UK Markets closed

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.6728+0.0428 (+6.79%)
At close: 04:00PM EDT
0.6500 -0.02 (-3.39%)
After hours: 07:57PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 323.3400
52-week low 30.5900
50-day moving average 31.3492
200-day moving average 35.1810

Share statistics

Avg vol (3-month) 3483.03k
Avg vol (10-day) 3555.16k
Shares outstanding 552.04M
Implied shares outstanding 6N/A
Float 840.72M
% held by insiders 141.76%
% held by institutions 123.41%
Shares short (28 Apr 2022) 42.79M
Short ratio (28 Apr 2022) 46.17
Short % of float (28 Apr 2022) 45.42%
Short % of shares outstanding (28 Apr 2022) 44.86%
Shares short (prior month 30 Mar 2022) 42.3M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:2
Last split date 325 Mar 2021

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-74.20%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -27.31M
Net income avi to common (ttm)-122.32M
Diluted EPS (ttm)-0.4470
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)16.98M
Total cash per share (mrq)0.3
Total debt (mrq)2.72M
Total debt/equity (mrq)41.88
Current ratio (mrq)5.10
Book value per share (mrq)0.25

Cash flow statement

Operating cash flow (ttm)-23.49M
Levered free cash flow (ttm)-12.4M